Moomoo AIのまとめ
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
サイケデリック系治療薬に特化したバイオテック企業のClearmind Medicine Inc.は、カナダ証券取引所（CSE）からの任意の廃止承認を発表しました。廃止は2024年3月14日の取引終了時に効力を発揮する予定です。CMNDのシンボルでNASDAQにも上場しているClearmind Medicineは、廃止の主要な理由としてCSEでの取引高が低いことを挙げ、二重上場の維持に必要な費用や事務手続きがもはや正当化されないためと述べています。同社はNASDAQでマーケットを一元化することで、長期的な流動性と株主価値の向上を期待しています。Clearmind Medicineは、カナダの株主...すべて展開
サイケデリック系治療薬に特化したバイオテック企業のClearmind Medicine Inc.は、カナダ証券取引所（CSE）からの任意の廃止承認を発表しました。廃止は2024年3月14日の取引終了時に効力を発揮する予定です。CMNDのシンボルでNASDAQにも上場しているClearmind Medicineは、廃止の主要な理由としてCSEでの取引高が低いことを挙げ、二重上場の維持に必要な費用や事務手続きがもはや正当化されないためと述べています。同社はNASDAQでマーケットを一元化することで、長期的な流動性と株主価値の向上を期待しています。Clearmind Medicineは、カナダの株主がNASDAQListed証券を取引できるよう、多くのカナダのブローカーがその能力を持っているため、カナダの株主が引き続き株式を取引できることを保証しています。同社の焦点は、アルコール使用障害などの健康問題の治療法の開発にあり、サイケデリック系化合物の分野で15の特許ファミリーを保有しています。
役に立った
役に立たない